1st PHEIC was declared by WHO for Swine Flue (H1N1 Influenzas) in 2009 with 284,500 deaths with 763 million cases reported in 214 countries and was successfully contained by Receptol® used at 3 domestic & international airports in Mumbai by Mumbai International Airports Ltd. The Patented Receptol® oral spray (USA Patent # US 9,249,188 B2) is a new Immunity Drug (NID) providing mode of action in a vaccine like manner with active immunity, can be used for treatment and as preventative vaccine in dealing with current 2019-nCoV epidemic.

Receptol® consists of cell to cell communicator Nano informational peptides (Radha108) & Proline-Rich Polypeptides (PRPs) from Mammalian colostrum, Mother's 1st milk after birth of the child. Numerous Studies have shown that Receptol® spray will deliver nanopeptide crossing blood brain barrier and have great effectiveness in treating many immunity disease including all viral infections with in 3 months. As a natural product it have no side effects & can be taken safely by all age groups and are not species specific.

Receptol® showed great effectiveness in treatment of retrovirus such as HIV, Swine Flu and SARS like conditions caused by Coronavirus. An accelerated, prospective Phase III global and can be used for it prevention and treatment as broad spectrum Antiviral.

Dr. Pawan Saharan, with a vision to provide Health for all, Invented World's 1st Immunity Drug to prevent and treat AIDS, Swine Flue & other Immunity problems via Broad Spectrum Antiviral - RECEPTOL® that can be an Answer to Covid-19 based on Common Mode of Action after 18 years of R&D globally involving 25,301 human subjects.

Dr. Saharan coordinated RECEPTOL® Global Market Research by IPSOS, USA and IRMA, India suggesting 1 out of 3 citizens globally should use the product both as a preventive and treatment for all communicable /immune deficiency disorders in the next 5 years with an estimated market cap of US$ 13 billion by EY.

RECEPTOL® is pushing the boundaries of science by accelerating innovation, thus creating a paradigm shift in the Healthcare, Pharma & Wellness industry.

Receptol® Oral Spray Shield for Coronavirus Proposed Treatment & Prevention as Demonstrated in AIDS recent article published in American journal of Biotechnology & Immunology. [8 other articles on this subject in press with top peer reviewed Science & Medical Global Journals like New England Journal of Medicine, oldest Medical joirnal from Boston]

https://escientificpublishers.com/receptol-oral-spray-shield-for-coronavirus-proposed-treatment-prevention-as-demonstrated-in-aids-JBI-02-0007

 

 




   Receptol Oral Spray for Corona Virus Treatment and Prevention

A new coronavirus, declared as Global Health Emergency by WHO, 2019-nCoV was first identified in Wuhan, the capital of China's Hubei province, after people developed SARS like pneumonia. The incubation period (time from exposure to the development of symptoms) of the virus is 2-10 days and can be contagious during this time. Symptoms include fever, coughing, and breathing difficulties. Without a clear cause of 2019-nCoV, treatments with existing vaccines is not effective.

The Receptol® oral spray, Globally Patented (USA Patent # US 9,249,188 B2) is a new Immunity Drug (NID) providing mode of action in a vaccine like manner with active immunity, can be used for treatment and as preventative vaccine in dealing with current 2019-nCoV epidemic.

Receptol® consists of cell to cell communicator Nano informational peptides (Radha108) & proline-Rich Polypeptides (PRPs) from colostrum, Mother’s 1st milk after the birth of the child or calf.

Numerous Studies have shown that receptol spray will deliver nano peptide crossing blood brain barrier and have great effectiveness in treating many immunity disease including all viral infections.

As a natural product, Radha 108 Nanopeptides have no side effects which can be taken safely by all age and are not species specific.

Receptol show great effectiveness in treatment of retrovirus such as HIV, Swine Flue and SARS like conditions caused by Coronavirus.

An accelerated, prospective Phase III global efficacy and safety studies for Receptol (containing API of Radha 108 Nanopeptides) was conducted for HIV Positive patients with 10 years follow up showed significant resolution of all symptoms and pharmacological effects with low to NILL Viral Load.

Once RADHA108 series get absorbed in the blood stream through buccal mucosa or transdermal route and crosses the Blood Brain Barrier (BBB), they act on Pituitary gland in brain and cell to cell communicator informational proteins (RADHA108) in RECEPTOL® will active in mitigating cell fusion.

RADHA108 series has shown to dock on glycoprotein receptor on the cell surface and thus closing doors and windows for viral entry into the cell surface & immune cells in particular.

Coronaviruses is enveloped positive- RNA viruses characterized by club-like spikes that project from their surface. It has unusually large RNA genome, four main structural proteins. spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins as virus particles. S protein is cleaved by a host cell furin-like protease into two separate polypeptides noted S1 and S2. The initial attachment of the virion to the host cell is initiated by interactions between the S protein and its receptor. The S-protein/receptor interaction is the primary determinant for a coronavirus to infect a host species and also governs the tissue tropism of the virus. Receptol nanopeptides can block the attachment of S protein like In case of well-studied mode of action in treatment of retrovirus infection such as HIV and Swine flue.

Receptol oral spray invented via Dr Pawan Saharan, Founder, Biomix USA, Australia and INDIA ( www.biomix.in) can be an answer to prevent & treat current epidemic of 2019-nCoV.

Receptol’s RADHA108 series nanopeptide will not only dock on S glycoprotein receptor on the cell surface to mitigate cell fusion closing doors and windows for all viral entry but will also stimulate the maturation of immature thymocytes into either helper or suppressor T cells, T help cells will help produce antibodies against 2019nCoA, Suppressor T cells, on the other hand, deactivate other lymphocytes after an infection has been cleared to avoid damage to healthy tissues. Receptol will help to produce memory T cells, in order to expedite the production of antibodies for future infection in all human hosts.


 

 Vision

Health for all, via affordable & effective healthcare for the world

 Mission

Develop & manufacture cost effective safe natural product for prevention & treatment of life threatening diseases & immune disorders.

 Innovation

Our health is directly influenced by our immune system. A balanced and healthy immune system is of utmost importance for our body's ability to defend against infections. WHO proclaimed “It is our ability to create a healthy immune system that represents the greatest potential for gains in human Therefore, creating a healthy immune system via Mother’s 1st Milk: Colostrum & its derivatives harnesses maximum benefit towards human health”


About Innovator

Innovative Products

Patents

Receptol Book



"Receptol is the perfect blend of Ayurvedic and modern day science. Like Ayurvedas, Receptol itself provides holistic healthcare solution. Since this innovative product is prepared from 'Piyusha' (Colostrum), mothers first milk, it provides immunity for life. The roots of our product lie in the ancient science of Ayurvedas."



Receptol - An Answer to Covid -19 with 46 references.
»
»
»
»
»




News & Events
»
Over 3 million people in India suffer from HIV & TB
»
We had supplied Receptol at Mumbai International Airport during Swine Flu Pandemic during 2009 - 2010 under the MIAL agreement.
»
Receptol was also kept at Falguni Pathak's Dandia show in Mumbai, to Prevent Swine Flu from Spreding

More











Copyright © BIOMIX NETWORK LTD